Conversion Surgery in Metastatic Gastric Cancer and Cancer Dormancy as a Prognostic Biomarker
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choe, Hun Jee | - |
dc.contributor.author | Kim, Jin Won | - |
dc.contributor.author | Han, Song-Hee | - |
dc.contributor.author | Lee, Ju Hyun | - |
dc.contributor.author | Ahn, Sang-Hoon | - |
dc.contributor.author | Park, Do Joong | - |
dc.contributor.author | Kim, Ji-Won | - |
dc.contributor.author | Kim, Yu Jung | - |
dc.contributor.author | Lee, Hye Seung | - |
dc.contributor.author | Kim, Jee Hyun | - |
dc.contributor.author | Kim, Hyung-Ho | - |
dc.contributor.author | Lee, Keun-Wook | - |
dc.date.accessioned | 2024-07-18T00:30:25Z | - |
dc.date.available | 2024-07-18T00:30:25Z | - |
dc.date.issued | 2020-01 | - |
dc.identifier.issn | 2072-6694 | - |
dc.identifier.issn | 2072-6694 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/74886 | - |
dc.description.abstract | The role of conversion surgery in metastatic gastric cancer remains unclear. Cancer dormancy markers might have a role in predicting the survival in patients with conversion surgery. We identified 26 patients who went through conversion surgery, i.e., a curative-intent gastrectomy with metastasectomy after chemotherapy in initially metastatic gastric cancer. As controls, 114 potential candidates for conversion surgery who only received chemotherapy were included for the propensity score matching. Conversion surgery showed a significantly longer overall survival (OS) compared with only palliative chemotherapy (median-43.6 vs. 14.0 months, respectively, p < 0.001). This better survival in the conversion surgery group persisted even after propensity matching (p < 0.001), and also when compared to patients with tumor response over 5.1 months in the chemotherapy only group (p = 0.005). In the conversion surgery group, OS was longer in patients with R0 resection (22/26, 84.6%) than without R0 resection (4/26, 15.4%) (median-not reached vs 22.1 months, respectively, p = 0.005). Although it should be interpreted with caution due to the primitive analysis in a small population, the positive expression of NR2F1 showed a longer duration of disease-free survival (DFS) after conversion surgery (p = 0.016). In conclusion, conversion surgery showed a durable OS even in patients with initially metastatic gastric cancer when R0 resection was achieved after chemotherapy. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | MDPI | - |
dc.title | Conversion Surgery in Metastatic Gastric Cancer and Cancer Dormancy as a Prognostic Biomarker | - |
dc.type | Article | - |
dc.identifier.doi | 10.3390/cancers12010086 | - |
dc.identifier.bibliographicCitation | CANCERS, v.12, no.1 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000516826700086 | - |
dc.identifier.scopusid | 2-s2.0-85077342899 | - |
dc.citation.number | 1 | - |
dc.citation.title | CANCERS | - |
dc.citation.volume | 12 | - |
dc.type.docType | Article | - |
dc.publisher.location | 스위스 | - |
dc.subject.keywordAuthor | gastric cancer | - |
dc.subject.keywordAuthor | conversion surgery | - |
dc.subject.keywordAuthor | cancer dormancy | - |
dc.subject.keywordAuthor | nuclear receptor NR2F1 | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | GASTRECTOMY | - |
dc.subject.keywordPlus | CISPLATIN | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.